|  |
| --- |
|  |
| Book Name: | [**Medical Science: Trends and Innovations**](https://www.bookpi.org/bookstore/product/medical-science-trends-and-innovations-vol-1/) |
| Manuscript Number: | **Ms\_BPR\_5013** |
| Title of the Manuscript:  | **First cycle treatment in a case of an AML FAB M2 and COVID-19 pneumonia** |
| Type of the Article | **Book Chapter** |

**Special note:**

**A research paper already published in a journal can be published as a Book Chapter in an expanded form with proper copyright approval.**

**Source Article:**

**This chapter is an extended version of the article published by the same author(s) in the following journal.**

**Asian Hematology Research Journal, 4(1): 12-18, 2021.**

**Available:** [**https://journalahrj.com/index.php/AHRJ/article/view/52**](https://journalahrj.com/index.php/AHRJ/article/view/52)

|  |
| --- |
| PART 1: Comments |
|  | Reviewer’s comment**Artificial Intelligence (AI) generated or assisted review comments are strictly prohibited during peer review.** | Author’s Feedback *(Please correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)* |
| **Please write a few sentences regarding the importance of this manuscript for the scientific community. A minimum of 3-4 sentences may be required for this part.** | This manuscript is significant for the scientific community as it provides valuable insights into the potential effectiveness of venetoclax in treating newly diagnosed **COVID-19 pneumonia** in patients with **acute myeloid leukemia (AML)**. The case highlights how venetoclax, even at a controlled dose, contributed to a positive therapeutic response despite severe comorbidities such as **systemic inflammatory response syndrome (SIRS), thrombocytopenia, and anemia**. Given the high mortality risk of pneumonia in leukemia patients, understanding the role of venetoclax in such complex cases could help refine treatment strategies, particularly in immunocompromised individuals. The observed reduction in **monocyte count** further underscores its potential immunomodulatory effects, making this study a valuable contribution to both **oncology and infectious disease management**. |  |
| **Is the title of the article suitable?****(If not please suggest an alternative title)** | **Yes** |  |
| Is the abstract of the article comprehensive? Do you suggest the addition (or deletion) of some points in this section? Please write your suggestions here. | The abstract provides a clear overview of the case and highlights the effectiveness of **venetoclax** in treating **COVID-19 pneumonia** in a patient with **acute myeloid leukemia (AML)**. However, there are areas where clarity, structure, and completeness could be improved. Below are my suggestions:**Suggested Additions:**1. **Objective Statement:** Start with a brief statement outlining the study's purpose and significance in addressing leukemia patients with COVID-19 pneumonia.
2. **More Structured Summary:** Divide the abstract into key aspects: background, case details, treatment approach, results, and conclusion.
3. **Clinical Implications:** Briefly mention the broader relevance of these findings for clinicians treating similar patients.

**Suggested Deletions/Modifications:**1. **"One describes" →** Change to "This chapter describes" for better readability.
2. **"A 70 years old" →** Should be "A 70-year-old" for grammatical accuracy.
3. **Clarify disease progression:** The sequence of events—**endocarditis, third molar extraction, leukemia diagnosis, and COVID-19 pneumonia**—should be more clearly structured.
4. **Venetoclax dosage clarity:** Explicitly state why the dosage was maintained at 100 mg and whether this was a standard or experimental approach.
5. **Strengthen the Conclusion:** Instead of just stating the response was positive, discuss potential mechanisms and how this case may contribute to future treatment guidelines.
 |  |
| **Is the manuscript scientifically, correct? Please write here.**  | **Yes** |  |
| **Are the references sufficient and recent? If you have suggestions of additional references, please mention them in the review form.****-** | **Yes** |  |
| Is the language/English quality of the article suitable for scholarly communications? | It is suitable. |  |
| Optional/General comments |  |  |

|  |
| --- |
| **PART 2:**  |
|  | Reviewer’s comment | Author’s comment *(if agreed with the reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)* |
| **Are there ethical issues in this manuscript?**  |  |  |

**Reviewers:**

**Arvind Kumar Shukla, Pusan National University, South Korea**